GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (FRA:SP4P) » Definitions » EV-to-FCF

Achieve Life Sciences (FRA:SP4P) EV-to-FCF : -6.70 (As of May. 04, 2024)


View and export this data going back to . Start your Free Trial

What is Achieve Life Sciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Achieve Life Sciences's Enterprise Value is €152.31 Mil. Achieve Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-22.73 Mil. Therefore, Achieve Life Sciences's EV-to-FCF for today is -6.70.

The historical rank and industry rank for Achieve Life Sciences's EV-to-FCF or its related term are showing as below:

FRA:SP4P' s EV-to-FCF Range Over the Past 10 Years
Min: -8.49   Med: -0.45   Max: 5.7
Current: -6.68

During the past 13 years, the highest EV-to-FCF of Achieve Life Sciences was 5.70. The lowest was -8.49. And the median was -0.45.

FRA:SP4P's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 4.57 vs FRA:SP4P: -6.68

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-04), Achieve Life Sciences's stock price is €4.26. Achieve Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.403. Therefore, Achieve Life Sciences's PE Ratio for today is At Loss.


Achieve Life Sciences EV-to-FCF Historical Data

The historical data trend for Achieve Life Sciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences EV-to-FCF Chart

Achieve Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 -1.02 -1.55 -0.94 -3.61

Achieve Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.94 -3.12 -2.68 -2.80 -3.61

Competitive Comparison of Achieve Life Sciences's EV-to-FCF

For the Biotechnology subindustry, Achieve Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achieve Life Sciences's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's EV-to-FCF falls into.



Achieve Life Sciences EV-to-FCF Calculation

Achieve Life Sciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=152.306/-22.731
=-6.70

Achieve Life Sciences's current Enterprise Value is €152.31 Mil.
Achieve Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-22.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Achieve Life Sciences  (FRA:SP4P) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Achieve Life Sciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.26/-1.403
=At Loss

Achieve Life Sciences's share price for today is €4.26.
Achieve Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.403.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Achieve Life Sciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Achieve Life Sciences (FRA:SP4P) Business Description

Traded in Other Exchanges
Address
22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.

Achieve Life Sciences (FRA:SP4P) Headlines

No Headlines